Marie Lachâtre, Armelle Pasquet, Faïza Ajana, Benoit Soudan, Georges Lion, Laurence Bocket, Pauline Cornavin, Eric Senneville, Faroudy Boufassa, Antoine Chéret
Male hypogonadism is poorly defined in people living with HIV. Using a reliable free-testosterone assay, we examined the prevalence and risk factors of male hypogonadism among people living with HIV on effective antiretroviral therapy. Male hypogonadism was found in 12.4% of patients, twice the rate reported in the general population of the same age. Two risk thresholds, namely 5 years of antiretroviral therapy and 19% total body fat, may help to identify patients at risk.
January 28, 2017: AIDS